Couban, S., Benevolo, G., Donnellan, W., Cultrera, J., Koschmieder, S., Verstovsek, S., Hooper, G., Hertig, C., Tandon, M., Dimier, N., Malhi, V., & Passamonti, F. (2018). A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology and Oncology, 11(1), Article 122. https://doi.org/10.1186/s13045-018-0661-x
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. /
Couban, Stephen; Benevolo, Giulia; Donnellan, William et al.
In:
Journal of Hematology and Oncology, Vol. 11, No. 1, 122, 24.09.2018.
Research output: Contribution to journal › Article › peer-review
Couban, S, Benevolo, G, Donnellan, W, Cultrera, J, Koschmieder, S, Verstovsek, S, Hooper, G, Hertig, C, Tandon, M, Dimier, N, Malhi, V & Passamonti, F 2018, 'A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis', Journal of Hematology and Oncology, vol. 11, no. 1, 122. https://doi.org/10.1186/s13045-018-0661-x
Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S et al. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology and Oncology. 2018 Sept 24;11(1):122. doi: 10.1186/s13045-018-0661-x
Couban, Stephen ; Benevolo, Giulia ; Donnellan, William et al. / A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. In: Journal of Hematology and Oncology. 2018 ; Vol. 11, No. 1.
@article{4f624404674347f7bb69f832afa82dd7,
title = "A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis",
keywords = "Hedgehog pathway inhibitor, Hematologic malignances, Hematopoiesis, Myelofibrosis, Ruxolitinib, Vismodegib",
author = "Stephen Couban and Giulia Benevolo and William Donnellan and Jennifer Cultrera and Steffen Koschmieder and Srdan Verstovsek and Gregory Hooper and Christian Hertig and Maneesh Tandon and Natalie Dimier and Vikram Malhi and Francesco Passamonti",
note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2018",
month = sep,
day = "24",
doi = "10.1186/s13045-018-0661-x",
language = "English",
volume = "11",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",
}
TY - JOUR
T1 - A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
AU - Couban, Stephen
AU - Benevolo, Giulia
AU - Donnellan, William
AU - Cultrera, Jennifer
AU - Koschmieder, Steffen
AU - Verstovsek, Srdan
AU - Hooper, Gregory
AU - Hertig, Christian
AU - Tandon, Maneesh
AU - Dimier, Natalie
AU - Malhi, Vikram
AU - Passamonti, Francesco
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/9/24
Y1 - 2018/9/24
KW - Hedgehog pathway inhibitor
KW - Hematologic malignances
KW - Hematopoiesis
KW - Myelofibrosis
KW - Ruxolitinib
KW - Vismodegib
UR - http://www.scopus.com/inward/record.url?scp=85053820642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053820642&partnerID=8YFLogxK
U2 - 10.1186/s13045-018-0661-x
DO - 10.1186/s13045-018-0661-x
M3 - Article
C2 - 30249277
AN - SCOPUS:85053820642
SN - 1756-8722
VL - 11
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 122
ER -
